Therapeutic Vaccines for Ovarian Cancer
DOI:
https://doi.org/10.54097/e8gqya86Keywords:
Ovarian cancer; Immunotherapy; Cancer vaccine.Abstract
Ovarian cancer is widely recognized as one of the most aggressive gynecological malignancies. Chemotherapy based on platinum and maintenance therapy following surgery are the cornerstones of treatment for ovarian cancer. However, early detection of ovarian cancer is difficult, frequently resulting in metastasis at the time of diagnosis, which impacts the efficacy of surgical interventions, leading to elevated rates of recurrence and a bleak prognosis. Immunotherapy has demonstrated the potential for improved treatment of ovarian cancer. Currently, cancer vaccines represent a significant immunotherapeutic approach. Cancer vaccines are a therapeutic approach designed to activate the patient's immune system to target and eliminate cancer cells. These vaccines can include tumor antigens, antibodies, cytokines, etc. to stimulate and initiate an immune response against the tumor. In this review, I provided an overview of past research progress in different therapeutic vaccines for ovarian cancer, including their mechanisms of action and advancements in preclinical and translational studies.
Downloads
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3): 209-249.
Cronin, KA, Scott, S, Firth, AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022; 128(24): 4251-4284.
Lheureux, S.; Gourley, C.; Vergote, I.; Oza, A.M. Epithelial ovarian cancer. Lancet 2019, 393, 1240–1253.
Koole, S.N., van Driel, W.J. and Sonke, G.S. (2019), Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on. Cancer, 125: 4587-4593.
Zhang, A.W.; McPherson, A.; Milne, K.; Kroeger, D.R.; Hamilton, P.T.; Miranda, A.; Funnell, T.; Little, N.;de Souza, C.P.E.; Laan, S.; et al. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell 2018, 173, 1755–1769 e1722
Chow S, Berek JS, Dorigo O. Development of Therapeutic Vaccines for Ovarian Cancer. Vaccines (Basel). 2020 Nov 5;8(4):657.
Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N. Predicting Response to Anthracyclines in Ovarian Cancer. Int J Environ Res Public Health. 2022 Apr 2;19(7):4260.
Abd-Aziz N, Poh CL. Development of Peptide-Based Vaccines for Cancer. J Oncol. 2022 Mar 15; 2022:9749363.
Osman AEG, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021 Sep; 49:100825.
Fatemeh Zahedipour, Khadijeh Jamialahmadi, Parvin Zamani, Mahmoud Reza Jaafari,Improving the efficacy of peptide vaccines in cancer immunotherapy,International Immunopharmacology, Volume 123,2023,110721,ISSN 1567-5769
Guo L, Wang J, Li N, Cui J, Su Y. Peptides for diagnosis and treatment of ovarian cancer. Front Oncol. 2023 May 5;13:1135523.
Yamada A, et al. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004;27(1):60-72.
Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL. Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res. 2018 Jul 1;24(13):3014-3025.
Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008;14(9):2740-8.
Dijkgraaf EM, Santegoets SJAM, Reyners AKL, Goedemans R,Nijman HW, van Poelgeest MIE, et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 2015;6(31):32228e43.
Steinman RM. Decisions About Dendritic Cells: Past, Present, and Future. In:WE Paul, editor. Annual Review of Immunology, Vol 30. Palo Alto: Annual Reviews (2012). p. 1–22.
Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, et al. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology (2019) 8(11).
Zhang X, He T, Li Y, Chen L, Liu H, Wu Y, Guo H. Dendritic Cell Vaccines in Ovarian Cancer. Front Immunol. 2021 Jan 25;11:613773.
Pfannenstiel LW, Lam SSK, Emens LA, Jaffee EM, Armstrong TD. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol (2010) 263(1):79–87.
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al.Phase I/II randomized trial of dendritic cell vaccination with or withoutcyclophosphamide for consolidation therapy of advanced ovarian cancer infirst or second remission. Cancer Immunol Immunother (2012) 61(5):629–41.
Baek S, Kim YM, Kim SB, Kim CS, Kwon SW, Kim Y, Kim H, Lee H. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol. 2015 Jan;12(1):87-95.
Harimoto H, Shimizu M, Nakagawa Y, Nakatsuka K, Wakabayashi A,Sakamoto C, et al. Inactivation of tumor specific CD8(+) CTLs by tumorinfiltrating tolerogenic dendritic cells. Immunol Cell Biol (2013) 91(9):545–55.
Liefers-Visser JAL, Meijering RAM, Reyners AKL, van der Zee AGJ, de Jong S.IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.Cancer Treat Rev (2017) 60:90–9.
Beatty GL, O’Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, et al. First-inHuman Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res (2017) 23(13):3269–76.
Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021 Feb 25;20(1):41.
Gildiz S, Minko T. Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer. Pharm Res. 2023 Jan;40(1):123-144.
Lu L, Ma W, Johnson CH, Khan SA, Irwin ML, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine. 2023 Mar 17;41(12):2073-2083.
D. Chen, J. Wang, Y. Chen, C. Yang, Y. Zhang, H. Zhang, F.F. Shi, X.Y. Wang, J. DouMicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition J. Ovarian. Res., 6 (2013), p. 50
Xu H, Zhao F, Wu D, Zhang Y, Bao X, Shi F, Cai Y, Dou J. Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination. Biomed Pharmacother. 2023 May;161:114547.
Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023 Feb;9(2):122-139. doi: 10.1016/j.trecan.2022.10.003. Epub 2022 Nov 17.
Chavda, V.P.; Bezbaruah, R.; Athalye, M.; Parikh, P.K.; Chhipa, A.S.; Patel, S.; Apostolopoulos, V. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses 2022, 14, 759.
Cui C, Wang X, Lian B, Ji Q, Zhou L, Chi Z, Si L, Sheng X, Kong Y, Yu J, Li S, Mao L, Tang B, Dai J, Yan X, Bai X, Andtbacka R, Guo J. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study. J Immunother Cancer. 2022 Apr;10(4):e004307
Long, J.; Yang, Y.; Kang, T.; Zhao, W.; Cheng, H.; Wu, Y.; Du, T.; Liu, B.; Yang, L.; Luo, F.; et al.Ovarian cancer therapy by VSVMP gene mediated by a paclitaxel-enhanced nanoparticle. ACS Appl. Mater. Interfaces 2017, 9, 39152–39164.
Odunsi, K.; Matsuzaki, J.; Karbach, J.; Neumann, A.; Mhawech-Fauceglia, P.; Miller, A.; Beck, A.; Morrison, C.D.; Ritter, G.; Godoy, H.; et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc. Natl. Acad.Sci. USA 2012, 109, 5797–5802.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







